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Hepatitis C virus (HCV) non-structural 2 (NS2) encodes an essential protease activity responsible for pro-
cessing at the NS2–NS3 junction which represents an attractive antiviral target. Attempts to inhibit the
NS2 autoprotease with mechanism-based protease inhibitors and substrate peptides have had limited
success. We report a series of epoxide-containing small molecules capable of blocking NS2–NS3 prote-
olysis in vitro and demonstrate the potential for selectivity towards the NS2 autoprotease. A compound
within this series was able to perturb HCV genome replication in a subgenomic replicon system only
when polyprotein processing was dependent on NS2 autoprotease activity, in addition it inhibited repli-
cation of full length HCV. These ﬁndings suggest blocking HCV polyprotein processing through inhibition
of the NS2 autoprotease represents a viable route to exert an antiviral effect.
 2015 The Authors. Published by Elsevier B.V. This is anopenaccess article under the CCBY license (http://
creativecommons.org/licenses/by/4.0/).1. Introduction
Hepatitis C virus (HCV) is a global health burden infecting 3% of
the world’s population. As a positive sense RNA virus within the
Flaviviridae family HCV relies on proteolytic processing of a single
polyprotein to generate mature proteins. The structural proteins
Core and E1–E2, as well as p7, are processed by host proteases,
while the non-structural (NS) proteins responsible for genome
replication undergo maturation by virally encoded proteases.
Autoproteolysis occurs at the NS2–NS3 boundary via a cysteine
protease activity encoded principally within NS2 but enhanced
by the presence of the NS3 N-terminus (Schregel et al., 2009).
NS3 with its cofactor NS4A (NS3-4A) mediates subsequent
downstream cleavages to generate NS4B, NS5A and NS5B (Scheel
and Rice, 2013).Inhibitors of the NS3-4A protease that disrupt polyprotein pro-
cessing are now approved for the treatment of HCV infection. How-
ever, NS2 protease activity remains an unexplored target. NS2 plays
no direct roles in genome replication, as demonstrated by the abil-
ity of a subgenomic replicon (SGR) to replicate in the absence of NS2
(Lohmann et al., 1999). However, the unprocessedNS2–NS3 precur-
sor has reduced NS3 protease activity, potentially by reducing NS3
proteolysis kinetics or through reduced stability of NS3 (Welbourn
et al., 2005). Hence where NS3 is derived from a NS2–NS3 precur-
sor, as in the context of infectious virus, the activity of the NS2 auto-
protease is essential (Jones et al., 2007; Kolykhalov et al., 2000).
Mutational analysis and structural studies of the post-cleavage
NS2 protease domain propose that NS2 acts as a cysteine protease,
though the catalytic triad appears to adopt the geometry of a serine
protease (Lorenz et al., 2006). Due to the essential nature of the NS2
autoprotease it has been proposed as an attractive target for antivi-
rals that to date has not been explored (Rice, 2011).
A common route to develop a protease inhibitor is to incorpo-
rate an electrophilic ‘warhead’ so as to produce a mechanism-
based inhibitor (Powers et al., 2002). Such reactive warheads form
an irreversible covalent interaction with the active site residues,
but often lack selectivity. In contrast, an epoxide warhead forms
a covalent interaction with the nucleophilic catalytic residue only
when the epoxide is held non-covalently in the optimal
orientation. As such the rate limiting step in protease inhibition
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to optimally orientate the epoxide for nucleophilic attack
(Bihovsky et al., 1993). This transient interaction is usually mediat-
ed by a conjugated substrate peptide derivative and can be tailored
to the system, allowing epoxide-based protease inhibitors a greater
degree of selectivity (Powers et al., 2002). However, unlike the HCV
NS3-4A protease, which is inhibited by peptides corresponding to
the N-terminus of the cleavage site (Llinas-Brunet et al., 1998),
the NS2 autoprotease shows little or no sensitivity to substrate
or proteolysis product peptides in vitro, nor to substrate peptides
conjugated to mechanism-based protease inhibitors (Pallaoro
et al., 2001; Thibeault et al., 2001). In addition, the cysteine pro-
tease inhibitor E64, an epoxysuccinyl peptide, has proven inactive
against the NS2 autoprotease (Pieroni et al., 1997; Thibeault et al.,
2001). We therefore sought to explore the activity of epoxide war-
heads conjugated to non-peptide derivatives, in particular a range of
reported cis-bisamido epoxides conjugated to aromatic ‘backbones’
which show activity against the cysteine containing active site of
factor XIIIa (Avery et al., manuscript submitted). Derivatives of this
scaffold showed activity against the NS2 autoprotease in vitro.
Importantly, the epoxide alone was insufﬁcient for activity and var-
iations to the aromatic backbone altered inhibitory activity, indicat-
ing the requirement for a transient interaction and suggesting
epoxide based inhibitors can be tailored to the NS2 active site. Epox-
ide based inhibitors of the NS2 autoprotease exerted an effect in cell
based assays in which HCV genome replication was NS2-dependent.
To the best of our knowledge these ﬁndings represent the ﬁrst
example of direct pharmacological inhibition of the NS2 autopro-
tease to block HCV genome replication and exert an antiviral effect.
2. Materials and methods
2.1. Compounds
Synthesis and analysis of compounds 1–10 has been reported
elsewhere (Avery et al., manuscript submitted). Tosyl phenylala-
nine chloromethyl ketone (TPCK) was from VWR International.
E64 and Telaprevir were from Sigma Aldrich and MedChem
Express respectively. All compounds were conﬁrmed by mass
spectrometry analysis using a VG Autospec mass spectrometer
with electron spray ionisation (ES) at 70 eV.
2.2. NS2–3 auto-processing assay
Expression of NS2–NS3-FLAG in pET23a has been previously
described (Foster et al., 2010; Tedbury and Harris, 2007) (Supple-
mentary material). NS2–3 at 20 lM in 6 M GdnHCl was diluted
1:100 into Refolding buffer (30% glycerol, 0.5% CHAPS, 250 mM
NaCl, 3 mM cysteine, 50 lM ZnCl2, 10 mM DTT, 50 mM HEPES–
NaOH, pH 7.0) and incubated 16 h RT. Compounds (133  ﬁnal
concentration in DMSO) were diluted into Refolding buffer before
the addition of NS2–3 to yield required ﬁnal concentrations. Reac-
tions were halted by the addition of 1=4 volume 4  Laemmli buffer
(200 mM Tris–HCl pH 6.8, 40% glycerol, 8% SDS, 0.08% bromophe-
nol blue, 20 mM DTT) and analysed by 15% SDS–PAGE and western
blot using M2 anti-FLAG monoclonal antibody (Sigma Aldrich) fol-
lowed by IRDye 680RD Donkey anti-Mouse secondary (LI-COR Bio-
sciences). Imaging and analysis was performed using Odyssey
imager (LI-COR Biosciences). Intensity of the 20 kDa proteolysis
product (NS3-FLAG) was quantiﬁed to calculate 50% effective con-
centration (EC50) using Prism 6 (GraphPad).
2.3. SGR compound treatments
Stable cell lines harbouring SGR (Supplementary material)
were maintained in Dulbecco’s modiﬁed Eagle’s medium (DMEM;Sigma) supplemented with 10% foetal bovine serum (FBS), 100 IU
penicillin ml1, 100 lg streptomycin ml1, 1% non-essential amino
acids and 300 lg/ml G418 (Sigma) in a humidiﬁed incubator at
37 C in 5% CO2. Cells were seeded at a density of 2  104 cells/well
in a 96 well plate. After 16 h media was removed and replaced with
media supplemented with the indicated concentrations of
compounds with standard DMSO at 0.25%. Plates were incubated
in the absence of G418 for a further 48 h.
2.4. Fireﬂy luciferase endpoint assay
Luciferase activity was quantiﬁed by addition of 30 ll Passive
Lysis Buffer (PLB: Promega) and addition of 40 ll LarI reagent (Pro-
mega) using a BMG Labtech plate reader with light emission
recorded over 6 s. Data was normalised to DMSO control. Statistical
signiﬁcance was determined using the Student’s t test.
2.5. Cell viability endpoint assay
Cellular metabolism was quantiﬁed by 2 h incubation in 1 mM
Thiazolyl Blue Tetrazolium Bromide (Sigma Aldrich) before crystals
were suspended in 100 ll DMSO and absorbance at 570 nm mea-
suredusingan inﬁnite F50platereader (Tecan).Datawasnormalised
to DMSO control. CC50 was calculated using Prism 6 (GraphPad).
2.6. HCVcc compound treatments
Transcripts (5 lg) of a Jc1 derivative expressing Nanoluciferase
(JC1-NLuc) (Amako et al., 2015)were electroporated into Huh7 cells
(see Supplementary). Compound was added as in Section 2.3. Cell
viabilitywasperformedas in Section2.5 following4%paraformalde-
hyde ﬁxation of cells. NanoLuc was measured using a BMG Labtech
plate reader following addition of 50 ll PLB and addition of equal
volume of NanoGlo Luciferase Assay Substrate (Promega).3. Results
3.1. The NS2 autoprotease is inhibited by halomethyl ketones but not
the epoxide-based inhibitor E64
To assess the ability of a small molecule to inhibit NS2 protease
activity, an in vitro auto-processing assay was employed. A NS2–
NS3 precursor protein (NS2–3) comprising the catalytic C-terminal
domain of NS2 and the N-terminal protease domain of NS3 (JFH1
polyprotein residues 906–1209, J4 residues 904–1206) ﬂanked by
an N-terminal His tag and C-terminal FLAG tag was bacterially
expressed and puriﬁed from inclusion bodies under denaturing con-
ditions by immobilised metal ion afﬁnity chromatography (IMAC).
Upon dilution into Refolding buffer, NS2–3 forms signiﬁcant sec-
ondary structure (Foster et al., 2010) allowing the autoprotease to
become active. This can be monitored by western blot analysis of
NS2–3 refolding reactions with an anti-FLAG antibody to reveal
35 kDa precursor NS2–3-FLAG and 20 kDa NS3-FLAG, one of the
proteolysis products. Quantiﬁcation of the proteolysis product
was used as a relative measure of NS2 autoprotease activity.
Puriﬁed NS2–3 of the genotype 2a isolate JFH1 and the
genotype 1b isolate J4 were both capable of auto-processing under
these conditions. NS2 autoprotease activity was inhibited by
EDTA (Fig. 1A), consistent with a structural requirement for zinc.
As previously reported (Pallaoro et al., 2001; Pieroni et al., 1997;
Thibeault et al., 2001), autoprotease activity was inhibited by the
halomethyl ketone tosyl phenylalanine chloromethyl ketone
(TPCK) (Fig. 1B) with an EC50 of 15.3 lM. NS2 was not inhibited
by E64 (Fig. 1C), conﬁrming previous observations (Pieroni et al.,
1997; Thibeault et al., 2001).
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Fig. 1. In vitro NS2–3 refolding to assay NS2 autoprotease activity. (A) Puriﬁed NS2–
3 of the genotype 2a isolate JFH1 (left panel) and genotype 1b isolate J4 (right panel)
produce detectable NS3-FLAG proteolysis product upon refolding. Addition of EDTA
(10 mM) blocks autoproteolysis-induced NS3-FLAG production. (B) JFH1 NS2–3
autoproteolysis was treated with indicated concentrations of tosyl phenylalanine
chloromethyl ketone (TPCK) and compared to a reaction halted before refolding
(0 h) and DMSO (0.75%) control. EC50 was calculated from quantiﬁed NS3-FLAG
normalised to DMSO control (plotted as 100 lM). (C) JFH1 NS2–3 autoproteolysis
produced comparable NS3-FLAG proteolysis product in the absence () or presence
(+) of E64 (300 lM).
Table 1
Activity of a range of epoxide based inhibitors of NS2–3 autoproteolysis. EC50
calculated from 10-point dose response curve against JFH1 NS2–3 refolding reaction
(Supplementary Fig. 1). CC50 calculated from 11-point dose response curve against
Huh7 cells (Supplementary Fig. 2).
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22 J. Shaw et al. / Antiviral Research 117 (2015) 20–263.2. Aromatic bis-amido based epoxides as inhibitors of the NS2
autoprotease
To test the ability of non-peptide derived epoxides to inhibit the
NS2 autoprotease, a range of previously reported compounds
containing an epoxide conjugated to a functionalised benzene ring
(Avery et al., manuscript submitted) were tested in the in vitro
auto-processing assay. Structures for these compounds are shown
in Table 1.
Compound 1 was identiﬁed as capable of blocking in vitro
NS2–NS3 processing in a dose responsive manner for both JFH1
and J4 isolates, with J4 showing enhanced sensitivity (Fig. 2).
Interestingly, a derivative lacking only the benzene 3-chloro group
(2) appeared inactive up to 300 lM (Fig. 2B). This ﬁnding indicated
that elements other than the epoxide alone contributed to the
inhibitory effect observed.
To further explore the contributions of the benzene substituents
to activity, a range of compounds containing the same epoxide as 1
with alternate R1 groups (Table 1) were tested against the JFH1
NS2–3 auto-processing assay. These molecules are all active tovarying degrees against factor XIIIa (Avery et al., manuscript
submitted), and are derived from the anti-factor XIIIa activity of
the epoxide-based natural product cerulenin, which contains an
extended hydrocarbon chain. Cerulenin showed no activity against
the NS2 autoprotease (Table 1). Activities of these compounds
(3–9) are shown in Table 1.
A number of chemical modiﬁcations reduced activity of 1 to
below the level of detection – these included removal of the 3-
chloro substituent from the benzene (2), introduction of a 4-bromo
substituent without (3) or with the 3-chloro group (4) and pres-
ence of 3,4-dimethyl groups (5). Compounds 7 and 8, with a 4-
amino-phenyloxy or 4-nitro-phenyloxy substituent respectively,
showed some activity but to a lesser extent to that shown by 1,
though a 3-phenyloxy substituent did enhance activity (6). The
most potent inhibitor was a 4-benzyloxy, 3-chloro substituted
derivative (9) yielding an EC50 of 55 lM. The varying activity of
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Fig. 2. Epoxide based inhibitors of the NS2 autoprotease. (A) JFH1 NS2–3 refolding
reactions were treated with indicated concentrations of 1 alongside controls and
NS3-FLAG proteolysis product (arrowhead) was quantiﬁed by western blot.
EC50 = 92 lM. (B) Identical treatment of JFH1 NS2–3 refolding reactions with 2.
EC50 = >300 lM. (C) J4 NS2–3 refolding reactions treated as in A. EC50 = 79 lM.
Chemical structures are shown in Table 1.
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late activity. In agreement with this, the epoxide alone, where the
functionalised amido-benzene backbone is replaced by a primary
alcohol (10), was inactive (Table 1, Supplementary Fig. 1).R
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Fig. 3. Comparative analysis of sub-genomic replicon (SGR) stable cell lines. (A)
Schematic of ﬁreﬂy luciferase–neomycin phosphotransferase (ffLuc–NPT) reporter
SGRs comprising NS3-5B or NS2-5B. (B) Luciferase activity (RLU – relative luciferase
units) from stable SGR harbouring cell lines analysed after indicated timepoints
post seeding (N.D. – not determined). Data represents the average of three technical
repeats ± SD. Lysates were analysed by western blot and probed with anti-JFH1 NS2
antibody and anti-GAPDH antibody alongside a control lysate from JFH1 infected
cells.3.3. Activity of epoxide based inhibitors in a cell based assay
In other systems, the requirement of epoxide-based inhibitors
to form a transient interaction with the protease before becoming
covalently linked allows them greater selectivity and makes them
more amenable to in vivo applications (Powers et al., 2002). To
explore the potential for bis-amido based epoxide warheads to
exert an inhibitory effect within a HCV model system, compounds
1–10 and cerulenin were tested for cytotoxic effects by calculating
CC50 from 72 h incubation in a hepatoma cell line capable of sup-
porting HCV replication (Supplementary Fig. 2). Of the compounds
showing signiﬁcant activity in vitro only 1 and 7 exerted no sig-
niﬁcant cytotoxicity up to 100 lM (Table 1). The activity of 1 in cell
based assays was further explored due to the availability of 2
which, as an inactive derivative without signiﬁcant cytotoxic
effects, allows a comparative tool.
In order to test for speciﬁc activity against NS2-dependent HCV
replication, stable cell lines were selected that harbour a HCV SGR
comprising either NS2-5B or NS3-5B of the JFH1 or Con1 isolates
(Fig. 3A). These replicons contain a fused ﬁreﬂy luciferase neomy-
cin phosphotransferase-reporter enabling both stable selection and
luciferase production as a measure of HCV replication (Wyles et al.,
2009). All replicon cell lines displayed reported sensitivity to
cyclosporine A (data not shown). Replication kinetics as measured
by luciferase activity were comparable in the absence or presenceof NS2 for both genotypes (Fig. 3B). Western blot conﬁrmed the
presence of mature NS2 (JFH1 strain only due to genotype-speciﬁc
antibody reactivity) while sequence analysis of SGR RNA extracted
from the stable cell lines did not reveal any additional culture
adaptive mutations.
To assess activity against HCV genome replication, SGR-JFH1-
NS2-5B was treated with 1 (at in vitro EC5090 lM) and the same
concentration of the inactive derivative 2. Quantiﬁcation of
luciferase activity revealed reduction to 48.1 ± 10.7% of vector con-
trol upon treatment with 1 (Fig. 4A), whereas 2 had no effect. Cell
viability was unaffected by 1, indicative that the decreased lucifer-
ase activity represented a speciﬁc inhibitory effect against genome
replication. The same treatment was performed in parallel against
SGR-JFH1-NS3-5B, which lacks the NS2 coding sequence and can
therefore support HCV replication independent of NS2 autopro-
tease activity. Treatment of this replicon cell line with 1 (90 lM)
produced a slight decrease in luciferase activity which correlated
with a decrease in cellular metabolism and was not statistically
signiﬁcant, indicating that 1 exerts no inhibitory activity against
NS2-independent HCV replication (Fig. 4A). To conﬁrm there are
no signiﬁcant differences between the response to inhibitor
treatment across the two cell lines, both were treated with an
intermediate concentration of the NS3-4A protease inhibitor
Telaprevir (Kwong et al., 2011). For both SGR-JFH1-NS2-5B and
SGR-JFH1-NS3-5B, addition of Telaprevir (150 nM) produced a
comparable reduction in luciferase activity with no effect on
cellular metabolism (Fig. 4A).
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Fig. 4. Cell based activity of epoxide based inhibitors of the NS2 autoprotease. (A) SGR-JFH1 cell lines containing ([NS2-5B]) or lacking ([NS3-5B]) NS2 were treated in parallel
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an increased potency against the genotype 1b J4 isolate (Fig. 2).
To explore whether this difference in genotype sensitivity was
observed in the context of HCV genome replication, 1 was tested
in parallel against SGR-JFH1-NS2-5B and SGR-Con1-NS2-5B. While
treatment with 1 (90 lM) produced a 47.8 ± 10.3% effect againstJFH1 SGR, the same treatment of a Con1 SGR reduced luciferase
activity by 94 ± 1%, with a similar toxicity proﬁle (Fig. 4B). As with
SGR-JFH1-NS2-5B, SGR-Con1-NS2-5B showed no sensitivity to
treatment with 2.
Finally, epoxides 1 and 2 were tested against a chimeric infec-
tious clone derived from genotype 2a isolates; Jc1 and containing
J. Shaw et al. / Antiviral Research 117 (2015) 20–26 25a Nanoluc reporter gene (Jc1-NLuc). Following electroporation of
Jc1-NLuc RNA into Huh7 cells treatment with 1 reduced reporter
activity to 14.8 ± 5.4% of control (Fig. 4C). Hence in the context of
a transient assay with infectious HCV, 1 exhibited enhanced antivi-
ral activity compared to a stable SGR system. This effect most likely
reﬂects the differences between transient and stable systems for
monitoring HCV replication, as it was also observed upon treat-
ment with Telaprevir (Fig. 4).4. Discussion
The NS2 autoprotease is essential in the HCV lifecycle and with
no homology to any human proteases represents an attractive drug
target. Recent evidence suggests processing of the NS2–NS3 junc-
tion may represent a rate limiting step in the onset of HCV genome
replication (Madan et al., 2014), hence the virus lifecycle may prove
particularly susceptible to inhibition of the NS2 autoprotease.
Despite concerted efforts, identiﬁcation of NS2 inhibitors has been
hampered by weak activities of classical protease inhibitors and
substrate peptides. Mechanism-based protease inhibitors conjugat-
ed to peptide derivatives, such as E64, or to NS2 substrate peptides
have shown no inhibitory activity, suggesting the modiﬁcation of
peptide substrates may not be a viable route for the development
of an NS2 autoprotease inhibitor. Herewe report the use of bis-ami-
do aromatic scaffolds conjugated to an epoxide warhead as inhibi-
tors of the NS2 autoprotease. Treatment of NS2–3 auto-processing
reactions with epoxides conjugated to small, non-peptide back-
bones reduced production of the NS3-FLAG proteolysis product in
a dose responsive manner. Importantly, these inhibitory effects
did not appear to be imparted solely by the epoxide, as modiﬁca-
tions to the ‘backbone’ of epoxy-bis-amido derivatives altered
activity. Such scaffolds might be modiﬁed to introduce selectivity
to the NS2 autoprotease active site. While a degree of structure-
relationship analysis has already been performed in vitro for this
series, future work should attempt to increase the potency of
inhibition before consideration as a clinical candidate.
Epoxide-derived mechanism-based inhibitors have been report-
ed to show selectivity to cysteine proteases over serine or aspartyl
proteases (Powers et al., 2002) and to speciﬁc target proteases
within this class (Schiefer et al., 2013). In agreement, cerulenin
and other epoxysuccinyl peptides display little reactivity to free
thiols in the form of glutathione (Powers et al., 2002) (Avery
et al., manuscript submitted). The observation of selectivity with
these molecules suggest that epoxide warheads could be targeted
to the NS2 autoprotease to increase both activity and selectivity
through the use of a backbone scaffold not derived from peptide
substrates. The inactivity of peptide conjugated mechanism-based
inhibitors could be attributed to size, in line with the inactivity of
cerulenin.
Observations made in the in vitro NS2–3 auto-processing assay
were also made in the context of HCV genome replication. A con-
centration of 1 active against the NS2 autoprotease in vitro exhib-
ited an inhibitory effect speciﬁc to NS2-dependent HCV genome
replication whereas 2, inactive in vitro, also showed no activity in
the same SGR cell lines. Furthermore, a genotype difference in
sensitivity to 1 was observed both in vitro and in the context of
NS2-dependent HCV replication, where enhanced sensitivity was
observed against genotype 1b compared to 2a. Compound 1 there-
fore appears more potent against genotype 1b than genotype 2a
both in vitro and in HCV model systems and it would be of interest
to extend this analysis to other genotypes. Encouragingly 1 showed
increased activity against full length infectious HCV compared to
that observed against stable SGR harbouring cells. This suggests
that, as expected, preexisting replication complexes present in
stable SGR-harbouring cells are resistant to NS2 inhibitors.Although the compounds described here are unlikely to be taken
forward to the clinic, the current data represent the ﬁrst reported
example of direct pharmacological inhibition of the NS2 autopro-
tease to block HCV genome replication and exert an antiviral effect
and thus provide proof of principle that the NS2 autoprotease is a
valid target for future development.
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